The Federal Joint Comitee (G-BA) as well as the authorising health insurance companies have published the first evaluation report on the indication BK (breast cancer) for the year 2022.
This website uses exactly two cookies in order to offer you the best possible user experience on our website. Cookie information is stored in your browser and is used to recognize you when you return to our website. The cookie saves your language setting as well as your cookie setting and is valid for one year after approval.
Necessary cookies should be activated at all times so that we can save your decision for the cookie settings.
If you deactivate this cookie, we cannot save your settings. This means that the next time you visit this website you will be asked for your cookie-settings again. In addition, we cannot save your language setting.
